Purdue pulls Palladone over alcohol risk

Share this article:

Purdue Pharma withdrew its Palladone painkiller from the market at the request of the Food and Drug Administration, which cited an "unacceptably high level of patient risk" over adverse interaction with alcohol.
The withdrawal dealt the Stamford, Conn.-based, privately-owned firm another harsh blow just days after it announced it was slashing its workforce by 825, or 38 percent, following a federal appeals court ruling that invalidated patents for its biggest-selling drug, OxyContin, clearing the way for generic competition.
Pallone won approval only last October for the management of persistent moderate to severe pain in patients requiring continuous pain relief for an extended period of time. The drug, launched in February, was prescribed to 11,500 patients, said Purdue. By contrast, OxyContin is prescribed to millions and makes up three-quarters of the company's sales. 
In a statement, the company said it was weighing the possibility of seeking approval to market Palladone in certain institutional settings, such as hospitals and in-patient hospices, per FDA permission. 
"Palladone was launched by Purdue with clear and strong warnings about alcohol interaction," the statement said. "Purdue believed these warnings, and modifications to our Risk Management Program, appropriately addressed this risk. Yesterday, the FDA advised Purdue that it has concluded that the risk of alcohol interaction cannot be adequately managed with warnings."

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.